discontinuing glp-1 Treatment Associated With Up to 60% Weight Regain, With Brajan Budini Discontinuing GLP-1s Before or Early

To avoid a gap in medication, make sure to track your enrollment period and start the renewal process well before the current coverage expires

If you see GLP-1/GIP, it is tirzepatide

Eli Lilly is expected to have its new obesity asset on the market with the triple-agonist retatrutide, reinforcing the shift towards portfolio led strategies that address different stages of treatment and patient needs rather than relying on a single flagship product

In a separate 16-week trial, liraglutide improved hormones in obese men with functional hypogonadism, meaning low testosterone was likely related to obesity

That includes protein

Those taking the highest dose of semaglutide lost an average of 6.2%. High-dose orforglipron users saw blood sugar reduced by 1.91% on average, compared to 1.47% for semaglutide. These results show that orforglipron is more effective for weight loss and blood sugar management than the currently available doses of oral semaglutide